Affiliation: Novartis Institutes for BioMedical Research
- Furet P, Masuya K, Kallen J, Stachyra Valat T, Ruetz S, Guagnano V, et al. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. Bioorg Med Chem Lett. 2016;26:4837-4841 pubmed publisher..This work forms the foundation of the discovery of HDM201, a second generation p53-MDM2 inhibitor that recently entered phase I clinical trial. ..